Biology Reference
In-Depth Information
117. Nishina K, Unno T, Uno Y, Kubodera T, Kanouchi T, Mizusawa H, Yokota T (2008) Efficient
in vivo delivery of siRNA to the liver by conjugation of [alpha]-tocopherol. Mol Ther
16(4):734-740
118. Wolfrum C, Shi S, Jayaprakash KN et al (2007) Mechanisms and optimization of in vivo
delivery of lipophilic siRNAs. Nat Biotech 25(10):1149-1157
119. Howard KA, Thomas NW, Jenkins PG, Davis SS, O'Hagan DT (1994) The absorption of
microparticles into Peyer's patches of the rabbit and rat. Pharm Sci Commun 4(4):207-216
120. Jepson MA, Clark MA, Foster N, Mason CM, Bennett MK, Simmons NL, Hirst BH (1996)
Targeting to intestinal M cells. J Anat 189(Pt 3):507-516
121. Malik B, Goyal AK, Markandeywar TS, Rath G, Zakir F, Vyas SP (2011) Microfold-cell tar-
geted surface engineered polymeric nanoparticles for oral immunization. J Drug Target:
20(1):76-84. doi:10.3109/1061186x.2011.611516
122. Rajapaksa TE, Stover-Hamer M, Fernandez X, Eckelhoefer HA, Lo DD (2010) Claudin
4-targeted protein incorporated into PLGA nanoparticles can mediate M cell targeted deliv-
ery. J Control Release 142(2):196-205
123. Jepson MA, Clark MA, Hirst BH (2004) M cell targeting by lectins: a strategy for mucosal
vaccination and drug delivery. Adv Drug Deliv Rev 56(4):511-525
124. Kim S-H, Seo K-W, Kim J, Lee K-Y, Jang Y-S (2010) The M cell-targeting ligand promotes
antigen delivery and induces antigen-specific immune responses in mucosal vaccination.
J Immunol 185(10):5787-5795
125. Rescigno M, Urbano M, Valzasina B, Francolini M, Rotta G, Bonasio R, Granucci F,
Kraehenbuhl J-P, Ricciardi-Castagnoli P (2001) Dendritic cells express tight junction proteins
and penetrate gut epithelial monolayers to sample bacteria. Nat Immunol 2(4):361-367
126. McConnell EL, Basit AW, Murdan S (2008) Measurements of rat and mouse gastrointestinal
pH, fluid and lymphoid tissue, and implications for in-vivo experiments. J Pharm Pharmacol
60(1):63-70
127. Plevy SE, Targan SR (2011) Future therapeutic approaches for inflammatory bowel diseases.
Gastroenterology 140(6):1838-1846
128. Triantafillidis JK, Merikas E, Georgopoulos F (2011) Current and emerging drugs for the
treatment of inflammatory bowel disease. Drug Des Devel Ther 5:185-210
129. Alexander NJ, Baker E, Kaptein M, Karck U, Miller L, Zampaglione E (2004) Why consider
vaginal drug administration? Fertil Steril 82(1):1-12
130. Petta CA, Faundes A, Dunson TR, Ramos M, Delucio M, Faundes D, Bahamondes L (1998)
Timing of onset of contraceptive effectiveness in Depo-Provera users: part I. Changes in
cervical mucus. Fertil Steril 69(2):252-257
131. Rahbek UL, Nielsen AF, Dong M, You Y, Chauchereau A, Oupicky D, Besenbacher F, Kjems
J, Howard KA (2010) Bioresponsive hyperbranched polymers for siRNA and miRNA deliv-
ery. J Drug Target 18(10):812-820
132. Rahbek UL, Howard KA, Oupicky D, Manickam DS, Dong M, Nielsen AF, Hansen TB,
Besenbacher F, Kjems J (2008) Intracellular siRNA and precursor miRNA trafficking using
bioresponsive copolypeptides. J Gene Med 10(1):81-93
Search WWH ::
Custom Search